Scott Martin’s son was still a newborn when nurses began to suspect the baby had hemophilia. The diagnosis sent Martin and his wife into a tailspin for about six months - then they began searching for treatment.

Three years later, frustrated by the lack of options, Martin, a Texas energy executive, pooled his wealth with John Taylor, a New York financial services executive whose own son is a hemophiliac, to launch a biotechnology firm, now based in Cambridge, focused on discovering a cure for the bleeding disorder.